Home
/
Lipocine Inc.
/
Financials
/
Quarterly
Lipocine Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Lipocine Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$114.6K
Nov 6, 2025
Q2
2025
Jun 30, 2025
$622.8K
Aug 5, 2025
Q1
2025
Mar 31, 2025
$93.9K
May 8, 2025
Q3
2025
Sep 30, 2024
$7.71M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$89.6K
Aug 5, 2025
Q1
2025
Mar 31, 2024
$7.62M
May 8, 2025
Q3
2024
Sep 30, 2023
($3.12M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
$55.0K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$55.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$500.0K
Nov 8, 2023
Q3
2020
Sep 30, 2020
$0
Nov 10, 2020
Q3
2020
Sep 30, 2019
$165.0K
Nov 10, 2020
Q2
2019
Jun 30, 2019
$0
Aug 7, 2019
Q1
2019
Mar 31, 2019
$0
May 8, 2019
Q3
2019
Sep 30, 2018
$0
Nov 12, 2019
Q2
2018
Jun 30, 2018
$0
Aug 7, 2018
Q1
2019
Mar 31, 2018
$428.0K
May 8, 2019
Q3
2018
Sep 30, 2017
$0
Nov 7, 2018
Q2
2018
Jun 30, 2017
$0
Aug 7, 2018
Q1
2018
Mar 31, 2017
$0
May 7, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2023
Jun 30, 2023
$55.0K
Aug 10, 2023
Q1
2023
Mar 31, 2023
$55.0K
May 11, 2023
Q3
2022
Sep 30, 2022
$500.0K
Nov 9, 2022
Q2
2023
Jun 30, 2022
$500.0K
Aug 10, 2023
Q3
2022
Sep 30, 2021
$55.0K
Nov 9, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.19M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($2.21M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($1.86M)
May 8, 2025
Q3
2025
Sep 30, 2024
($2.22M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($3.07M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
$3.51M
May 8, 2025
Q3
2024
Sep 30, 2023
($6.65M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($3.55M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($3.87M)
May 9, 2024
Q3
2023
Sep 30, 2022
($2.41M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($2.63M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($3.49M)
May 11, 2023
Q3
2022
Sep 30, 2021
($3.08M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($6.81M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($3.37M)
May 9, 2022
Q3
2021
Sep 30, 2020
($4.31M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($6.37M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($5.77M)
May 6, 2021
Q3
2020
Sep 30, 2019
($3.06M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($3.43M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.36M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($2.40M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($2.09M)
May 8, 2025
Q3
2025
Sep 30, 2024
($2.63M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($3.29M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
$3.22M
May 8, 2025
Q3
2024
Sep 30, 2023
($7.04M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($3.96M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($4.34M)
May 9, 2024
Q3
2023
Sep 30, 2022
($2.90M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($3.53M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($3.13M)
May 11, 2023
Q3
2022
Sep 30, 2021
($3.53M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($2.99M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($3.11M)
May 9, 2022
Q3
2021
Sep 30, 2020
($4.38M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($4.22M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($4.60M)
May 6, 2021
Q3
2020
Sep 30, 2019
($2.98M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($3.35M)
Aug 6, 2020